Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L) - George, L A; Thalji, N K; Raffini, L J; Gimotty, P A; Camire, R M (Journal of thrombosis and haemostasis, 2015)
Keywords: Blood Coagulation - drug effects; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Factor VIIa - pharmacology; Factor VIII - immunology; Factor Xa - pharmacology; Hemophilia A - blood; Hemophilia A - drug therapy; Hemophilia A - immunology; Hemostatics - pharmacology; Humans; Isoantibodies - immunology; Male; Mutagenesis, Site-Directed; Recombinant Proteins - pharmacology; Thrombelastography; Time Factors; coagulation time, whole blood; factor X, activated; deficiency, factor VIII; hemophilia A, congenital; hemophilia B; inhibitor, blood coagulation factor